LEN vs PRLD · rev $34.19B vs rev $6.5M
LEN (LEN) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
LEN currently screens at market cap $0. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the LEN and PRLD stock pages for the full models.
Not investment advice.